Remdesivir is considered a key antiviral drug in the fight against COVID-19, especially in adult patients with severe complications
The government said on Wednesday that the country’s seven remdesivir makers have been urged to ramp up production to full capacity by next week.
The directive goes against reports of shortages of the critical drug. Remdesivir is considered a key antiviral drug in the fight against COVID-19, especially in adult patients with severe complications.
“There are seven players who are producing remdesivir. I have asked all players to increase production to full capacity by next week. The API for the drug is made in India so there will be no problem, “Mansukh Mandaviya, Minister of State for Chemicals and Fertilizers, said PTI.
Mr Mandaviya said that these seven manufacturers – Mylan, Hetero, Jubiliant Life Sciences, Cipla, Dr Reddy’s, Zydus Cadila and Sun Pharma – have a monthly production capacity of 31.60 lakh vials.
Letters have been sent to all of these drug makers to speed up production, he added.
Of the 31.60 lakh vials, Hetero produces 10.50 lakh vials per month, Cipla makes 6.20 lakh vials, 5 lakh vials are produced by Zydus Cadila and 4 lakh vials are produced by Mylan, Mr Mandaviya said.
The remaining drug makers produce vials in the range of 1 lakh to 2.5 lakh per month, he added.
The Madhya Pradesh government has decided to procure injections of remdesivir so that they can be provided free of charge for the treatment of critical COVID-19 patients from economically weaker sections.